$0.49
NASDAQ:
RENB
-0.01 ( -2.53% )
Pricing delayed by 20 minutes
Last updated: 04/10/2024 16:00 EST
RENOVARO CUBE
Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.
For more information on Renovaro Cube, go to their website at renovarocube.com
RENOVARO BIO
Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
For more information on Renovaro Biosciences, go to their website at renovarobio.com
News Items
September 19, 2024
PersonalAIze and Cube Forge Groundbreaking Partnership
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes.
September 17, 2024
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform
Assessment by specialist Ai team from “PersonalAIze” Highlights the Strenght, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform.
September 13, 2024
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
September 11, 2024
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of Cube, currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB.
Information request form
Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.
a future free from toxic chemotherapy